World Neuroscience Innovation Forum to be Held at London’s Francis Crick Institute
Partners HealthCare, a Boston-based hospital system that includes Brigham and Women’s Hospital and Massachusetts General Hospital, and whose faculty teach at Harvard Medical School, today announced the first World Neuroscience Innovation Forum, which will bring together senior corporate executives, top clinicians, venture investors, and leading researchers from the U.S. and Europe to battle diseases that afflict one in six people around the world. The Forum will take place at the Francis Crick Institute in London on March 27, 2017.
“Neurodegenerative and related diseases are among the greatest challenges confronting contemporary society and their enormous growth represent a potential economic cataclysm. This global gathering of some of the world’s top neuroscience leaders will catalyze new connections, conversations and thinking around these unprecedented challenges,” said Rudolph E. Tanzi, Ph.D., Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital, and Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School.
The Forum will launch the Springboard Challenge, an award competition that will seed new international, multi-sector neuroscience teams dedicated to the development of disruptive approaches to improve therapeutics and diagnostics to treat neurodegenerative (NDD) or neuroinflammatory (NID) diseases. The Challenge will offer three awards of $50,000 each and mentorship support from leading UK and US venture capitalists. The awards are intended to fund team meetings, logistics, and strategic planning efforts for the proposed solution. Collaborations enabled by the awards will seek multi-year support from Forum industry sponsors, governments, investors, foundations and other organizations. Award selections will be made in the summer of 2017.
“Alzheimer’s and other neurological diseases such as epilepsy, multiple sclerosis and Parkinson’s afflict one in six people around the world and a truly global effort is needed to combat them. The World Forum will support and enhance that effort by inspiring the kind of interactions and collaborations that can lead to life-changing products and therapies,” said Anne Klibanski, M.D., Chief Academic Officer for Partners HealthCare and the Forum’s organizer.
The Forum will feature highly interactive panel discussions on topics ranging from investment priorities to therapies to the impact of neurodegeneration on the health care system, as well as keynote sessions with Biogen and Eli Lilly.
“The complexity of discovering treatment for neurodegenerative diseases requires an innovative and collaborative approach in order to advance the knowledge we have about these conditions,” said Michael Ehlers, M.D., Ph.D., Executive Vice President, Research and Development, Biogen. “Biogen is committed to researching and developing treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Through our support of events like the World Neuroscience Innovation Forum, we hope to accelerate the discovery of new medicines for the people who need them.”
“Lilly is committed to battling neurodegenerative diseases,” said John C. Lechleiter, Chairman of the Board, Lilly. “The World Forum will be an important milestone in the efforts to unravel the complexity of these diseases and act on them to help millions of patients around the world.”
Sponsors of the Forum include Biogen, Lilly, GSK, Pfizer, the Francis Crick Institute, the High Lantern Group, Imperial College Health Partners, Janssen Neuroscience and MedCity.
For more information or to register, please go to http://neuroscienceinnovationforum.org/.
Partners HealthCare is a Boston-based integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners is the largest academic research organization in the Unites States and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.
The Francis Crick Institute is a unique partnership between the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London.
Rich Copp, 617-278-1031
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom